Company profile
Day One Biopharmaceuticals, Inc.
Pipeline3 assets
- TovorafenibDAY101 / OJEMDA / RAF / MAPK pathway / Oral small-molecule type II RAF inhibitor / OncologyBRAF-altered relapsed pLGGApprovedOJEMDA received FDA accelerated approval; FIREFLY-1 pivotal Phase 2 follow-up ongoing/disclosedU.S.Frontline RAF-altered pLGGPhase 3 / RegistrationalFIREFLY-2 pivotal Phase 3
- Emiltatug ledadotinEmi-Le / B7-H4 / Antibody-drug conjugate (ADC) / OncologyAdenoid cystic carcinoma (ACC), adult and pediatric solid tumorsPhase 1B7-H4-targeted ADC; Phase 1 data anticipated mid-2026 per company investor materials
- DAY301MTX-13 / CB-002 / PTK7 / Antibody-drug conjugate (ADC) / OncologyAdult and pediatric solid tumorsPhase 1Phase 1a data anticipated 2H 2026 per company investor materials
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.